FEMASYS INC — SEC Form D Filing

FEMASYS INC filed an SEC Form D on August 20, 2026, reporting $30.00M raised in Medical Devices.

Form D filing details

Filing
SEC Form D
Filing date
August 20, 2026
Amount reported
$30.00M
Round stage
Series B+
Industry
Medical Devices
Website
https://femasys.com/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Women face a fertility crisis where existing IVF treatments are often too expensive, invasive, and inaccessible. Additionally, many women seeking permanent contraception desire non-surgical alternatives.

Solution

Femasys develops office-based, minimally invasive solutions for women's reproductive healthcare, including FemaSeed for earlier fertility treatment and FemBloc for non-surgical permanent birth control.

Why now

The increasing cost and invasiveness of traditional fertility treatments like IVF, coupled with a growing demand for less invasive and more accessible women's health solutions, create a timely market for Femasys's products.

Verdict

Investors saw a clear path to commercialization for a focused medical device play addressing well-understood women's health needs. This cleared because it offered a less invasive, office-based solution for common reproductive issues, not because it promised a revolutionary new treatment paradigm. The implicit bet was on adoption by existing physician networks and favorable reimbursement codes, rather than creating new markets or patient behaviors. Upside was limited by the need for clinical validation, regulatory hurdles, and physician training, common for medical devices.

Source: SEC EDGAR Form D filing